Literature DB >> 8162610

Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects.

D Yang1, M Satoh, H Ueda, S Tsukagoshi, M Yamazaki.   

Abstract

ONO-4007 is a novel synthetic analog of lipid A subunit and has been shown to exert antitumor activities on various experimental tumors with less toxicity than lipopolysaccharide. It remains unclear, however, what biological activities of this compound are relevant to its antitumor effects. We therefore investigated the activation of macrophages by ONO-4007 in vitro and in vivo and its implication in antitumor effects, using mouse MM46 mammary tumor as an experimental model. Intravenous injection of ONO-4007 produced significant therapeutic effects on this solid tumor. ONO-4007 could stimulate glycogen-elicited peritoneal macrophages in vitro, not only to produce tumor necrosis factor (TNF), but also to exert cytocidal activities against MM46 cells in vitro. Substantial TNF production was induced in tumor tissue by i. v. injection of ONO-4007, and its successive administration to tumor-bearing mice gave tumor-infiltrating macrophages a prominent in vitro tumoricidal activity and primed them for in vitro TNF secretion. These results suggest that activation of tumor-infiltrating macrophages to a direct tumoricidal state as well as to TNF secretion in tumor tissues may be at least some of the antitumor effects of this novel lipid A analog.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8162610     DOI: 10.1007/bf01525505

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  20 in total

Review 1.  The origin and function of tumor-associated macrophages.

Authors:  A Mantovani; B Bottazzi; F Colotta; S Sozzani; L Ruco
Journal:  Immunol Today       Date:  1992-07

Review 2.  Bacterial endotoxins and host immune responses.

Authors:  D C Morrison; J L Ryan
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

3.  A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF.

Authors:  M Kriegler; C Perez; K DeFay; I Albert; S D Lu
Journal:  Cell       Date:  1988-04-08       Impact factor: 41.582

4.  A simple method for counting adherent cells: application to cultured human monocytes, macrophages and multinucleated giant cells.

Authors:  A Nakagawara; C F Nathan
Journal:  J Immunol Methods       Date:  1983-01-28       Impact factor: 2.303

5.  Purification and physico-chemical characterization of rabbit tumor necrosis factor.

Authors:  M R Ruff; G E Gifford
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

6.  Intratumoral tumor necrosis factor induction in tumor-bearing mice by exogenous/endogenous tumor necrosis factor therapy as compared with systemic administration of various biologic response modifiers.

Authors:  T Nishizawa; T Okutomi; H Inagawa; A Morikawa; H Oshima; G Soma; D Mizuno
Journal:  Mol Biother       Date:  1991-12

7.  Induction of nitric oxide synthase is a necessary precondition for expression of tumor necrosis factor-independent tumoricidal activity by activated macrophages.

Authors:  R Keller; S Bassetti; R Keist; A Mülsch; S Klauser
Journal:  Biochem Biophys Res Commun       Date:  1992-05-15       Impact factor: 3.575

8.  Combination antitumor therapy with lentinan and bacterial lipopolysaccharide against murine tumors.

Authors:  S Abe; O Yoshioka; Y Masuko; J Tsubouchi; M Kohno; H Nakajima; M Yamazaki; D Mizono
Journal:  Gan       Date:  1982-02

9.  The antitumor function of tumor necrosis factor (TNF) II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma.

Authors:  R J North; E A Havell
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

10.  Human tumor-infiltrating lymphocytes transfected with tumor necrosis factor gene could augment cytotoxicity to autologous tumor cells.

Authors:  Y Itoh; Y Kohgo; N Watanabe; Y Kanisawa; S Sakamaki; M Takahashi; Y Hirayama; H Ono; T Himeno; Y Niitsu
Journal:  Jpn J Cancer Res       Date:  1991-11
View more
  7 in total

1.  A synthetic lipid A mimetic modulates human TLR4 activity.

Authors:  Matteo Piazza; Valentina Calabrese; Gaetana Damore; Roberto Cighetti; Theresa Gioannini; Jerrold Weiss; Francesco Peri
Journal:  ChemMedChem       Date:  2011-12-02       Impact factor: 3.466

2.  Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats.

Authors:  N Onier; S Hilpert; L Arnould; V Saint-Giorgio; J G Davies; J F Jeannin; J F Jeannin
Journal:  Clin Exp Metastasis       Date:  1999-06       Impact factor: 5.150

3.  Role of inflammatory mediators in lipid A analogue (ONO-4007)-induced vascular permeability change in mouse skin.

Authors:  H Ishida; E Fujii; K Irie; T Yoshioka; T Muraki; R Ogawa
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

4.  Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Lorenzo Galluzzi; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

5.  Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.

Authors:  Z Cao; W R Joseph; W L Browne; K G Mountjoy; B D Palmer; B C Baguley; L M Ching
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

6.  Spirulina lipopolysaccharides inhibit tumor growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to interferon-γ.

Authors:  Hiromi Okuyama; Akira Tominaga; Satoshi Fukuoka; Takahiro Taguchi; Yutaka Kusumoto; Shiro Ono
Journal:  Oncol Rep       Date:  2017-01-02       Impact factor: 3.906

7.  A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors.

Authors:  Y Nihei; Y Suga; Y Morinaga; K Ohishi; A Okano; K Ohsumi; T Hatanaka; R Nakagawa; T Tsuji; Y Akiyama; S Saito; K Hori; Y Sato; T Tsuruo
Journal:  Jpn J Cancer Res       Date:  1999-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.